Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s Pharmaceutical TechnologyThe real-world data study tracked Parkinson's disease patients for 12 months during treatment with AbbVie's VyalevNeuroscienceRead full story pharminent July 1, 2026 (Last updated: July 1, 2026) Pharmaceutical Technology The real-world data study tracked Parkinson’s disease patients for 12 months during treatment with AbbVie’s Vyalev Neuroscience Read full story Post navigation Previous: Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory failNext: Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program Related Stories Clinical Data Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts pharminent September 2, 2026 Clinical Data Novartis says MS pill succeeds in two large studies pharminent September 1, 2026 Clinical Data ESC 2026: Evolocumab explores new frontiers in CV disease prevention pharminent August 31, 2026